muscle cramp study

Muscle Cramp Study Underway

by | Mar 20, 2018 | 1 comment

muscle cramp study

Flex Pharma

Flex Pharma, Inc. is a biotechnology company developing innovative treatments for cramps and spasticity associated with severe neurological diseases, such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS) and peripheral neuropathies such as Charcot-Marie-Tooth (CMT). In October 2017, Flex Pharma initiated a Phase 2 study of CMT, referred to as the COMMIT study. The study will evaluate FLX-787, the Company’s co-activator of TRPA1 and TRPV1, in patients with CMT who suffer from muscle cramps. Approximately 120 subjects at 20 study centers across the United States are expected to take part. Participants will be in the study for approximately three months and will visit the study clinic three times. Enrollment is currently ongoing.COMMIT logo

“Many of our patients with CMT neuropathy suffer from frequent and severe muscle cramping which can limit their activities of daily living and have a profound impact on their quality of life,” reported CMT clinical trial lead investigator, Dr. Nicholas Johnson, Assistant Professor of Neurology, Pediatrics and Pathology at the University of Utah. “We are hopeful FLX-787 will provide significant clinical advantages because of its safety profile and the lack of systemic exposure.” 

Dr. William McVicar, Flex Pharma President and CEO, added “An important goal of the Hereditary Neuropathy Foundation (HNF) is to raise awareness of inherited neuropathies, such as CMT. Flex Pharma and the HNF both support research aimed at addressing the needs of patients, so we are excited to be partnering with the HNF in this effort to find a treatment for CMT patients suffering from painful cramps that impact their quality of life.” 


Learn more on this topic

Related Blog Posts

Pharnext Announces PXT3003 for the Treatment of Charcot-Marie-Tooth Disease Type 1A has Been Granted Promising Innovative Medicine (PIM) Designation by UK Medicines and Healthcare Products Regulatory Agency

United Kingdom’s Medicine and Healthcare products Regulatory Agency (MHRA) has granted Promising Innovative Medicine (PIM) designation to its lead drug candidate, PXT3003, for the treatment of Charcot-Marie-Tooth Disease Type 1A (CMT1A) in patients 16 years and older.

Pharnext raises € 7.7 million in a private placement

Pharnext SA (FR0011191287 – ALPHA) (the “Company”), a biopharmaceutical company pioneering a new approach to developing innovative drug combinations based on its PLEOTHERAPY artificial intelligence platform harnessing big genomics data and network pharmacology, today announced a capital raise of circa € 7.7 million by way of issuance of 1,799,061 new ordinary shares (the “New Shares”) with one warrant attached each (together with the New Shares, the “ABSA”).

Join the conversation

Leave a Comment

1 Comment

  1. Larry Ruddle

    Any chance Hershey Medical Center, Penn State is involved in any of the studies


Submit a Comment

Your email address will not be published. Required fields are marked *


Join for notifications on events, campaigns, & news